Braunschweig Hospital Pioneers New Treatment for Severe Aortic Regurgitation

Braunschweig Municipal Hospital has introduced a new treatment for patients with severe aortic regurgitation. The procedure uses the JenaValve Trilogy, a minimally invasive option that expands care for those with limited alternatives. Three patients have already received the therapy this week at the hospital's cardiac centre.

The JenaValve Trilogy is designed specifically for aortic insufficiency, unlike older TAVI systems that focus on aortic stenosis. Its unique clip-and-anchor mechanism ensures stable positioning, even in valves without heavy calcification.

This new approach fills a critical gap in treatment options. Previously, many patients with severe regurgitation had few choices, often facing high-risk surgeries. The hospital's adoption of the technology follows its recent launch at the Herzzentrum in Bad Berka, which began offering the procedure around March 6, 2026. Currently, only ten clinics across Germany provide this catheter-based therapy. Braunschweig's cardiac centre is now among them, joining a small group of specialised facilities equipped to deliver the treatment.

The introduction of the JenaValve Trilogy at Braunschweig Municipal Hospital broadens access to a gentler alternative for high-risk patients. With three successful procedures completed, the centre aims to treat more individuals who previously lacked suitable options. The therapy's availability remains limited, with just a handful of German clinics offering it so far.